Journal
LANCET
Volume 379, Issue 9834, Pages 2364-2372Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(12)60738-7
Keywords
-
Categories
Funding
- UK Medical Research Council
- Stroke Association
- University of Edinburgh
- National Health Service Health Technology Assessment Programme
- Swedish Heart-Lung Fund
- AFA Insurances Stockholm (Arbetsmarknadens Partners Forsakringsbolag)
- Karolinska Institute
- Marianne and Marcus Wallenberg Foundation
- Research Council of Norway
- Oslo University Hospital
- Boehringer Ingelheim
- Medical Research Council [G0400069, G0700704B, G0800803] Funding Source: researchfish
- MRC [G0400069, G0800803] Funding Source: UKRI
Ask authors/readers for more resources
Background Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treated soon after acute ischaemic stroke in randomised trials, but licensing is restrictive and use varies widely. The IST-3 trial adds substantial new data. We therefore assessed all the evidence from randomised trials for rt-PA in acute ischaemic stroke in an updated systematic review and meta-analysis. Methods We searched for randomised trials of intravenous rt-PA versus control given within 6 h of onset of acute ischaemic stroke up to March 30, 2012. We estimated summary odds ratios (ORs) and 95% CI in the primary analysis for prespecified outcomes within 7 days and at the final follow-up of all patients treated up to 6 h after stroke. Findings In up to 12 trials (7012 patients), rt-PA given within 6 h of stroke significantly increased the odds of being alive and independent (modified Rankin Scale, mRS 0-2) at final follow-up (1611/3483 [46.3%] vs 1434/3404 [42.1%], OR 1.17, 95% CI 1.06-1.29; p=0.001), absolute increase of 42 (19-66) per 1000 people treated, and favourable outcome (mRS 0-1) absolute increase of 55 (95% CI 33-77) per 1000. The benefit of rt-PA was greatest in patients treated within 3 h (mRS 0-2, 365/896 [40.7%] vs 280/883 [31.7%], 1.53, 1.26-1.86, p<0.0001), absolute benefit of 90 (46-135) per 1000 people treated, and mRS 0-1 (283/896 [31.6%] vs 202/883 [22.9%], 1.61, 1.30-1.90; p<0.0001), absolute benefit 87 (46-128) per 1000 treated. Numbers of deaths within 7 days were increased (250/2807 [8.9%] vs 174/2728 [6.4%], 1.44, 1.18-1.76; p=0.0003), but by final follow-up the excess was no longer significant (679/3548 [19.1%] vs 640/3464 [18.5%], 1.06, 0.94-1.20; p=0.33). Symptomatic intracranial haemorrhage (272/3548 [7.7%] vs 63/3463 [1.8%], 3.72, 2.98-4.64; p<0.0001) accounted for most of the early excess deaths. Patients older than 80 years achieved similar benefit to those aged 80 years or younger, particularly when treated early. Interpretation The evidence indicates that intravenous rt-PA increased the proportion of patients who were alive with favourable outcome and alive and independent at final follow-up. The data strengthen previous evidence to treat patients as early as possible after acute ischaemic stroke, although some patients might benefit up to 6 h after stroke.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available